Immunogenicity and safety of Sanofi Pasteur's CYD dengue vaccine in healthy children and adolescents aged 9 to 16 years in Latin America
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2016
At a glance
- Drugs CYD TDV (Primary) ; DTaP vaccine
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 13 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2011 Planned end date changed from 1 Jan 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 03 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History